In peripheral artery disease, which medication class is indicated for all patients regardless of LDL and may improve leg symptoms?

In peripheral artery disease, which medication class is indicated for all patients regardless of LDL and may improve leg symptoms?

• A. Beta blockers
• B. Statins
• C. Calcium channel blockers
• D. ACE inhibitors

Answer: (B)

Statins are recommended for all patients with peripheral artery disease because these patients have a high risk of cardiovascular events, and lowering atherosclerotic risk improves overall outcomes. The guideline message is to start or continue statin therapy regardless of the initial LDL level, since the benefit extends beyond reducing LDL cholesterol alone. Statins have pleiotropic effects—such as improved endothelial function, anti-inflammatory actions, and plaque stabilization—that can modestly improve walking distance or leg symptoms in some individuals, in addition to lowering cardiovascular risk. Other medications listed aren’t universally indicated for all PAD patients to improve leg symptoms. Beta blockers, calcium channel blockers, and ACE inhibitors are useful for other cardiovascular or blood pressure indications, but they do not carry the same universal recommendation for PAD management and symptom improvement as statins do.

Statins are recommended for all patients with peripheral artery disease because these patients have a high risk of cardiovascular events, and lowering atherosclerotic risk improves overall outcomes. The guideline message is to start or continue statin therapy regardless of the initial LDL level, since the benefit extends beyond reducing LDL cholesterol alone. Statins have pleiotropic effects—such as improved endothelial function, anti-inflammatory actions, and plaque stabilization—that can modestly improve walking distance or leg symptoms in some individuals, in addition to lowering cardiovascular risk.

Other medications listed aren’t universally indicated for all PAD patients to improve leg symptoms. Beta blockers, calcium channel blockers, and ACE inhibitors are useful for other cardiovascular or blood pressure indications, but they do not carry the same universal recommendation for PAD management and symptom improvement as statins do.